The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass

American Journal of Obstetrics and Gynecology

Volumn 187, Issue 2, 2002, Pages 385-392

  Schutter, Eltjo M J ^a,b   Davelaar, Elvira M ^a   Van Kamp, Gerard J ^a   Verstraeten, Rob A ^a   Kenemans, Peter ^a   Verheijen, René H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

CA 125 antigen; CA 15 3 antigen; CA 72 4 antigen; Differential diagnosis; Logistic model; Ovarian carcinoma; Pelvic mass

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 72-4 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; PELVIS TUMOR; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL;

EID: 0036678619     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.123768     Document Type: Article

References (25)

1. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass: An international multicenter study
2. Specialist gynaecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients
3. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary
4. Preoperative serum tumor-associated antigen levels in women with pelvic masses
5. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3
6. The CA 125 tumour-associated antigen: A review of the literature
7. Carcinoma-associated mucin serum markers CA M26 and CA M29: Efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix
8. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer
9. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3
10. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses
11. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: An international multicenter study
12. The use of tumor markers in the differential diagnosis between ovarian and colorectal carcinoma
13. The effects of abdominal and bimanual pelvic examination and transvaginal ultrasonography on serum CA-125 levels
14. Drastic elevation of serum CA125, CA72-4 and CA19-9 levels during menses in a patient with probable endometriosis
15. Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values
16. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women
17. Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles
18. Serum and tissue measurements of CA72-4 in ovarian cancer patients
19. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI
20. The adnexal mass: Benign or malignant? Evaluation of a risk of malignancy index
21. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses
22. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer
23. A multivariate logistic regression analysis in predicting malignancy for patients with ovarian tumors
24. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
25. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses